Lecture 4 - Protein and lipid based drug delivery for brain injury and osteoarthritis/bone regeneration

The CURESUB Lecture Series

Monday, June 27th 2022
1:00 PM Eastern 
Zoom Link

Picture of Dr.Venkatesan

Dr. Venkatesan Perumal

Research Assistant Professor, New Jersey Institute of Technology



Dr. Venkatesan received B.Pharmacy degree in Pharmaceutical Science from Dr MGR Medical University, Tamil Nadu. He did his M.Tech in Biomedical Engineering from Jadavpur University, Kolkata, West Bengal. Then he joined Ph.D program in School of Medical Science and Technology of Indian Institute of Technology, Kharagpur as a full time institute research scholar. His areas of interests are Drug delivery, Pharmaceutics, Nanotechnology, Cancer Biology, Bone tissue engineering, Traumatic brain injury, Targeted drug delivery. He has published several papers in peer reviewed international journals, book chapters, invited talk and in international conference (including 3 US patents). He has been serving as editorial board member (in 3 journals) and reviewer member (in more than 10 journals) and judge (conferences in USA).

As a researcher for the past 10 years after Phd, he has been involved with undergraduates both from USA and India. Since 2011 he has mentored several graduate and undergraduate students’ students at Health Science Center, Texas A&M University, College Station, TX, USA, University of Colorado Denver, USA and Oklahoma State University, USA, trained them in heat sensitive liposomes formulation and gemcitabine/paclitaxe l loaded albumin nanoparticle by desolvation and microfluidizer, characterization, in vitro and in vivo mouse studies in athymic mouse tumor model (Prostate and colon). Currently he is working as a Research Assistant professor at New Jersey Institute of Technology.



Neurodegenerative disorders associated with traumatic brain injury (TBI) impose enormous health and societal burden worldwide. There is currently no clinically approved drug to treat TBI-mostly due to the inability to deliver the therapeutics to the brain. The objective of the study is formulation, characterization and in vivo biodistribution using transferrin receptor targeted (tf (transferrin)) conjugated minocycline loaded albumin nanoparticles in rat blast TBI model. A novel, tf conjugated minocycline encapsulated albumin nanoparticle was developed, characterized and quantified using a validated HPLC method. The current study indicates a promising, effective and safe means of using delivering minocycline in TBI with minimal or no toxicity for neuroprotective therapy. Similarly, treating osteoarthritis (OA) remains a major clinical challenge. Despite recent advances in drug discovery and development, no disease-modifying drug for knee OA has emerged with any notable clinical success, in part, due to the lack of valid and responsive therapeutic targets and poor drug delivery within knee joints. It was hypothesized that the inhibition of sPLA2 activity may be an effective treatment strategy for OA. To develop an sPLA2-responsive and lipid-based nanoparticle (NP)–based interventional platform for OA management, author incorporated an sPLA2 inhibitor (sPLA2i) into the phospholipid membrane of micelles. The engineered sPLA2i- loaded micellar NPs (sPLA2i-NPs) were able to penetrate deep into the cartilage matrix, prolong retention in the joint space, and mitigate OA progression. These findings suggest that sPLA2i-NPs can be promising therapeutic agents for OA treatment.

Worldwide, prostate cancer is the second most common cancer in terms of occurrence and sixth in terms of fatality in male. Due to chemotherapeutic resistance, no effective therapeutic regimen option is available to treat metastatic castration-resistant prostate cancer (CRPC). Toxicities associated with dose-limitations, solubility issue and poor drug release from nanocarriers lead to treatment failure. In order to resolve these issues, different composition of surfactants and lipids were utilized to formulate optimal docetaxel (Dtx) loaded low temperature sensitive liposomes (LTSL's) These liposomes demonstrated small, narrow hydrodynamic size distributions, hemocompatibility, high entrapment efficiencies and mild hyperthermia mediated Dtx release. In vitro studies showed significant cell cycle arrest/apoptosis and cytoplasmic uptake of released C6. The current study indicates a promising, effective delivery of Dtx using thermosensitive formulation to advance to detailed in vitro and in vivo analysis.